ArticleBMC psychiatry2026
Predictors of post-stroke depression and anxiety at three months following acute ischemic stroke.
Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPost-stroke depression (PSD) and post-stroke anxiety (PSA) are common emotional complications after acute ischemic stroke (AIS). We examined the incidence and risk factors for PSD alone, PSA alone, and their co-occurrence three months post-stroke.
methodsWe included 579 AIS patients who completed the Hospital Anxiety and Depression Scale (HADS) at discharge and 3 months later, using anxiety (HADS-A) and depression (HADS-D) subscales. Forty-one routinely collected parameters were analysed, including cognitive function (Montreal Cognitive Assessment) and oral health (Oral Health Impact Profile-14). Participants were grouped as: A - no PSA/PSD (n = 271), B - PSA only (n = 85), C - PSD only (n = 78), D - both PSA and PSD (n = 145).
resultsCompared with Group A, PSA was associated with female sex and anxiety at discharge; PSD with older age, ischemic heart disease, cognitive impairment, depression, and poorer functional outcomes; co-morbid PSA and PSD with female sex, infections, cognitive impairment, anxiety, depression, and worse discharge outcomes. Multivariate analysis showed PSA risk increased with anxiety at discharge (OR = 2.58; 98.3% CI:1.26-5.27), PSD risk with older age (OR = 1.05; 98.2% CI:1.01-1.09) and depression at discharge (OR = 3.99; 98.3% CI:1.61-9.80), and co-morbid risk with both anxiety (OR = 2.43; 98.3% CI:1.28-4.63) and depression at discharge (OR = 2.56; 98.3% CI:1.19-5.50).
conclusionsMood disorders affect up to 50% of stroke survivors, with co-morbid PSA and PSD most common. Early anxiety and depression at discharge strongly predict later emotional complications. Routine screening at discharge can identify high-risk patients and enable early interventions. Future studies should develop tailored psychological and rehabilitative strategies, that improve both mental health and functional recovery post-stroke. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.